Abstract：【Objective】 To explore the value of serum microribonucleic acid-146a (miR-146a) level combined with computerized tomography (CT) in the early diagnosis of lung cancer in elderly high-risk populations. 【Methods】 A total of 124 elderly patients at high risk of lung cancer,who were admitted to Shangluo International Medical Center Hospital from October 2019 to December 2020,were selected as the research subjects. Serum miR-146a measurement and CT examinations were performed. According to the diagnosis of clinical pathological results,patients were divided into the positive group (diagnosed as lung cancer patients) and negative group (no lung cancer patients). The serum miR-146a levels were compared between the positive group and the negative group. The CT examination results were compared with the pathological diagnosis results. The receiver operating characteristic curve (ROC) was drawn and the area under the curve (AUC) was used to evaluate the diagnostic efficacy of serum miR-146a combined with CT in the elderly high-risk population of lung cancer. 【Results】 Among the 124 elderly patients with high risk of lung cancer,78 were positive and 46 were negative. The level of serum miR-146a in the positive group was higher than that in the negative group (t=21.512,P<0.001). A total of 72 positive patients were detected by CT examination:the positive coincidence rate,negative coincidence rate and total coincidence rate were 84.62%,86.96%,and 85.48%,respectively. ROC analysis showed that the best cut-off of serum miR-146a for the diagnosis of elderly high-risk patients with lung cancer was 1.42,and the AUC of serum miR-146a combined with CT examination in the diagnosis of elderly high-risk patients with lung cancer was 0.906,which was higher than that of serum miR-146a and CT examination alone (Z=3.021,P=0.003; Z=2.289,P=0.022). 【Conclusion】 The diagnostic efficacy of serum miR-146a combined with CT scans is relatively high in elderly high-risk populations of lung cancer. It can be used as an important reference index for clinical evaluation.
代凤霞, 靳强. 血清miR-146a检测联合CT检查对肺癌老年高危人群的诊断价值[J]. 医学临床研究, 2023, 40(4): 585-588.
DAI Feng-xia, JIN Qiang. Application of Serum miR-146a Level Combined with CT Examination in the Early Diagnosis of Lung Cancer in High-risk Population. JOURNAL OF CLINICAL RESEARCH, 2023, 40(4): 585-588.
[1] 雷哲锋,王黄震. 人工智能阅片技术在老年早期肺癌辅助诊断中的应用价值[J].医学临床研究,2022,39(10):1590-1592.
[2] RUIZ-CORDERO R,DEVINE W P. Targeted therapy and checkpoint immunotherapy in lung cancer[J].Surg Pathol Clin,2020,13(1):17-33.
[3] 刘倩,黄明华,孙金林. 塞瑞替尼与克唑替尼治疗老年ALK融合基因阳性晚期非小细胞肺癌的疗效比较[J].医学临床研究,2022,39(3):393-396.
[4] 张秀玲. miR-146a靶基因IRAK1,TRAF6及其相关IncRNA HOXA11-AS对肺癌的作用及机制研究[D]. 南宁:广西医科大学,2019.
[5] 朱莉莉,袁新平. CT联合血清肿瘤标志物水平检测在周围型肺癌患者中的诊断价值[J].中国医师杂志,2019,21(10):1529-1532.
[6] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.
[7] HOUSTON T. Screening for lung cancer[J].Med Clin North Am,2020,104(6):1037-1050.
[8] OUDKERK M,LIU S,HEUVELMANS M A,et al. Lung cancer LDCT screening and mortality reduction-evidence,pitfalls and future perspectives[J].Nat Rev Clin Oncol,2021,18(3):135-151.
[9] MOHAMED R H,PASHA H F,GAD D M,et al. miR-146a and miR-196a-2 genes polymorphisms and its circulating levels in lung cancer patients[J].J Biochem,2019,81(3):42-46.
[10] DU H,LI Y,SUN R R,et al. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a[J].Thorac Cancer,2020,11(9):2473-2482.
[11] 袁芳. miR-146a对肺腺癌细胞恶性生物学行为影响及机制研究[D].福建:福建医科大学,2019.
[12] 陈辉国,周亚夫,颜建华,等. 肺癌miR-146a表达及其对细胞增殖,侵袭及迁移的影响[J].临床肿瘤学杂志,2020,25(3):37-42.
[13] 周舟,王道清. 胸部CT联合肿瘤标志物对早期老年人肺癌的诊断价值[J].中华老年医学杂志,2018,37(5):536-538.
2023, Vol. 40 
